Hydralazine injection how supplied storage and handling
| Hydralazine |
|---|
| HYDRALAZINE tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| HYDRALAZINE injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Hydralazine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
HOW SUPPLIED
 |
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
This container closure is not made with natural rubber latex.
N+ and NOVAPLUS are registered trademarks of Novation, LLC.
Manufactured by:
Fresenius Kabi USA, LLC
Lake Zurich, IL 60047
451104B
Revised: June 2013[1]
References
- ↑ "HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC]". Retrieved 10 March 2014.